IDEAYA Biosciences, Inc. (IDYA) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 5 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Nov 3, 2026before open 34 8-K
Q2 FY2026Tue, Aug 4, 2026before open 35 8-K
Q1 FY2026Tue, May 5, 2026before open 35 8-K
Q4 FY2025Tue, Feb 17, 2026before open 48 8-K
Q3 FY2025Tue, Nov 4, 2025before open 35 8-K
Q2 FY2025Tue, Aug 5, 2025before open 36 8-K
Q1 FY2025Tue, May 6, 2025before open 36 8-K
Q4 FY2024Thu, Feb 13, 2025before open 44 8-K

What they guided beta

Q3 FY2026 "Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) presented at ESMO 2026 demonstrates robust anti-tumor activity and encouraging survival benefit in relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC); initial data from IDEAYA-sponsored global Phase 1/2 trial expected by the end of 2026 / early 2027" exhibit
Q3 FY2026 "$1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026; cash runway guidance into 2030 remains unchanged based on current operating plan SOUTH SAN FRANCISCO, Calif., Nov. 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a business update." exhibit
Q3 FY2026 "IDE034 (B7H3/PTK7 bispecific TOP1 ADC): IDEAYA plans to provide initial clinical data from its ongoing Phase 1 dose escalation trial in 2027, which is expected to include preliminary safety and efficacy data." exhibit
Q3 FY2026 "Pursuant to the clinical collaboration announced with Roche in May, IDEAYA is also targeting initiation of a Phase 1 trial to evaluate IDE892 in combination with RG6505, Roche’s Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant PDAC by the end of 2026. o In August, IDEAYA entered into a Clinical Supply Collaboration Agreement with Genentech to evaluate IDE892 in combination with RG6620, a Phase 1 KRAS" exhibit
Q3 FY2026 "IDEAYA’s cash runway guidance into 2030 is unchanged based on the current operating plan." exhibit
Q2 FY2026 "Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026" exhibit
Q2 FY2026 "Announced clinical collaboration with Roche to evaluate IDE892 (PRMT5) in combination with RG6505 (pan-RAS) in MTAP-deleted, RAS-mutant pancreatic cancer; targeting to initiate a Phase 1 combination trial in H2 2026" exhibit
Q2 FY2026 "~$1.24 billion of cash, cash equivalents, and marketable securities as of June 30, 2026; cash runway guidance into 2030 is unchanged based on current operating plan SOUTH SAN FRANCISCO, Calif., Aug. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today reported financial results for the second quarter ended June 30, 2026, and provided a business update." exhibit
Q2 FY2026 "IDEAYA plans to provide an update on the OS data as part of the pre-specified interim analysis expected in mid-2027. o Overall, the darovasertib combination was generally well-tolerated with a manageable safety profile, consistent with previous results and known side-effects of each agent." exhibit
Q2 FY2026 "The company plans to present updated ORR, PFS and OS results from approximately 85 efficacy-evaluable HLA*A2:01-positive patients, including both first line and pre-treated patients, at the 2026 European Society of Medical Oncology (ESMO) Congress taking place in October in Madrid, Spain. o Data from OptimUM-01 will be included as part of IDEAYA’s NDA submission to the U.S. Food and Drug Administration (FDA) to support regulatory discussions that have the potential to expand the labeled indication of the darovasertib combination." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/IDYA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/IDYA

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

IDYA earnings date badge

HTML

<a href="https://veritasdata.dev/company/IDYA/"><img src="https://veritasdata.dev/embed/IDYA.svg" alt="IDYA earnings date" width="240" height="56"></a>

Markdown

[![IDYA earnings date](https://veritasdata.dev/embed/IDYA.svg)](https://veritasdata.dev/company/IDYA/)

Script

<script async src="https://veritasdata.dev/embed/IDYA.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/IDYA"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.